AC Immune (ACIU) Capital Expenditures (QoQ) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -84.64% |
| Sep 30, 2025 | 83.91% |
| Jun 30, 2025 | -11.90% |
| Mar 31, 2025 | -291.91% |
| Dec 31, 2024 | 47.33% |
| Sep 30, 2024 | -159.41% |
| Jun 30, 2024 | 73.64% |
| Mar 31, 2024 | -52.44% |
| Dec 31, 2023 | 40.97% |
| Sep 30, 2023 | -83.89% |
| Jun 30, 2023 | 20.28% |
| Mar 31, 2023 | -108.55% |
| Dec 31, 2022 | 2,119.04% |
| Sep 30, 2022 | 77.53% |
| Jun 30, 2022 | 4.64% |
| Mar 31, 2022 | -111.85% |
| Dec 31, 2021 | 1,014.88% |
| Sep 30, 2021 | 21.72% |
| Jun 30, 2021 | 21.18% |
| Mar 31, 2021 | -131.06% |
| Dec 31, 2020 | 1,135.73% |
| Sep 30, 2020 | 30.21% |
| Jun 30, 2020 | -77.57% |
| Mar 31, 2020 | 93.20% |
| Dec 31, 2019 | -795.32% |
| Sep 30, 2019 | -65.83% |
| Jun 30, 2019 | 364.55% |
| Mar 31, 2019 | -114.66% |
| Dec 31, 2018 | 2,577.27% |
| Sep 30, 2018 | 66.08% |
| Jun 30, 2018 | 63.29% |
| Mar 31, 2018 | -100.06% |
| Dec 31, 2017 | 197.71% |
| Sep 30, 2017 | -198,861.79% |
| Jun 30, 2017 | -56.51% |
| Mar 31, 2017 | -139.59% |
| Dec 31, 2016 | 582.02% |
| Sep 30, 2016 | -213.78% |
| Jun 30, 2016 | 52.72% |
| Mar 31, 2016 | -143.32% |